Alzheimer's Drug Shows Some Success (LLY, PFE, ELN)

Drugmaker Eli Lilly & Co. (NYSE: LLY) announced this morning that the company's solanezumab treatment for Alzheimer's disease failed to meet both the cognitive and functional endpoints in recently completed phase 3 double-blind trials. The Eli Lilly trials did yield some success though:

[A] pre-specified secondary analysis of pooled data across both trials showed statistically significant slowing of cognitive decline in the overall study population of patients with mild-to-moderate Alzheimer's disease. In addition, pre-specified secondary subgroup analyses of pooled data across both studies showed a statistically significant slowing of cognitive decline in patients with mild Alzheimer's disease, but not in patients with moderate Alzheimer's disease.

About a month ago, rivals Pfizer Inc. (NYSE: PFE) and Elan Corp. PLC (NYSE: ELN) said that their jointly developed Alzheimer's treatment, bapineuzumab, had failed late-stage trials.

The company's CEO/chairman/president said:

We recognize that the solanezumab studies did not meet their primary endpoints, but we are encouraged by the pooled data that appear to show a slowing of cognitive decline. We intend to discuss these data with regulatory authorities to gain their insights on potential next steps.

Eli Lilly's shares are up about 5% in premarket trading this morning, at $44.50 in a 52-week range of $34.94 to $44.67.

Paul Ausick


Filed under: 24/7 Wall St. Wire, Drug companies, Pharmaceuticals, Regulation Tagged: ELN, LLY, PFE
Read Full Story
  • DJI26788.10-39.54-0.15%
    NASDAQ8104.30-58.69-0.72%
  • NIKKEI 22522548.9056.220.25%
    Hang Seng26786.2060.520.23%
    DAX12754.696.730.05%
  • USD (PER EUR)1.11-0.0025-0.22%
    USD (PER CHF)1.01-0.0034-0.34%
    JPY (PER USD)108.45-0.1170-0.11%
    GBP (PER USD)1.29-0.0093-0.71%